Integral Diagnostics Ltd

IDX: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|$@B<>>LOCK|$hLOCK|>tWKGwp

Integral Diagnostics Earnings: Labor Costs Weigh on Margins, but Poised to Expand

No-moat Integral Diagnostic’s interim fiscal 2025 underlying Australian revenue grew a respectable 8%, driven by 5% average fee growth on increases in government funding and continued favorable mix impact, but was below industry growth of 11%. Underlying group EBITDA also grew 8% to AUD 47 million, but the market was clearly disappointed about profitability.

Sponsor Center